0000000000084128

AUTHOR

Daniela Castiglia

showing 3 related works from this author

Pharmacological Management of Elderly Patients with Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

2016

Asthma and chronic obstructive pulmonary disease (COPD) are two distinct diseases that share a condition of chronic inflammation of the airways and bronchial obstruction. In clinical settings, it is not rare to come across patients who present with clinical and functional features of both diseases, posing a diagnostic dilemma. The overlap condition has been termed asthma–COPD overlap syndrome (ACOS), and mainly occurs in individuals with long-standing asthma, especially if they are also current or former smokers. Patients with ACOS have poorer health-related quality of life and a higher exacerbation rate than subjects with asthma or COPD alone. Whether ACOS is a distinct nosological entity …

medicine.medical_specialtyExacerbationPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePharmacotherapyAdrenal Cortex HormonesAdministration InhalationPrevalencemedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineeducationAgedAsthmaCOPDeducation.field_of_studyLungbusiness.industryOverlap syndromemedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemQuality of LifePhysical therapyDrug Therapy CombinationSalmeterolGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct

Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis

2016

Background: Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc) up to two-third of the cases, representing the main cause of death in these patients. Assessment of lung involvement by HRCT and close monitoring of lung function are mandatory. At present no serologic biomarkers are validated for the assessment for lung damage in SSc. The current study was designed to test the hypothesis that the levels of surfactant are altered in SSc compared to healthy controls. To this aim serum levels of SP-A (Surfactant Protein A) and SP-D (Surfactant Protein-D) in serum were assessed. Methods: We enrolled 12 consecutive patients (M/F: 2/10) affected by scleroderma referred…

medicine.medical_specialtyPathologyLungbusiness.industryInterstitial lung diseaseSurfactant protein Dmedicine.diseaseGastroenterologyBlood proteinsSurfactant protein Amedicine.anatomical_structureDLCOInternal medicinemedicineBiomarker (medicine)Respiratory systembusiness1.5 Diffuse Parenchymal Lung Disease
researchProduct

Inhalation therapy in the next decade

2018

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyRespiratory TherapyEuropean Seminars in Respiratory MedicineCost-Benefit Analysiseducationlcsh:MedicineMedication adherenceSettore MED/10 - Malattie Dell'Apparato RespiratorioCOPD; European Seminars in Respiratory Medicine; Inhalation therapyINSPIRATORY FLOW-RATEHistory 21st CenturyOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease Chronic ObstructivePATIENT ADHERENCECOPD; European Seminars in Respiratory Medicine; Inhalation therapy; Pulmonary and Respiratory MedicineITALIAN GENERAL-PRACTITIONERSmedicinePulmonary MedicineHumansCOPDMortalityMEDICATION ADHERENCEIntensive care medicineAsthmaHEALTH-CARE PROFESSIONALSCOPDInhalationbusiness.industryDRY POWDER INHALERlcsh:ROBJECTIVELY IDENTIFIED COMORBIDITIESIMPROVES LUNG-FUNCTIONHistory 20th Centurymedicine.diseaseDry-powder inhalerAsthmarespiratory tract diseasesRespiratory MedicineREAL-LIFEItalyInhalation therapyFemaleCardiology and Cardiovascular MedicinebusinessMonaldi Archives for Chest Disease
researchProduct